Latest Huntingtin Stories
Ascent Scientific, together with Freie Universität Berlin, The University of Newcastle and Children's Medical Research Institute today announced that they have entered into an exclusive
Aging is a major risk factor for the progression of neurodegenerative diseases, including Huntington disease (HD).
CARLSBAD, Calif., Aug. 11, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and CHDI Foundation, Inc. announced today a renewal of their collaboration to discover and develop an antisense drug for the treatment of Huntington's disease (HD), a fatal neurodegenerative disorder.
A new study describes how hyperactivation of AMP-activated protein kinase (AMPK) promotes neurodegeneration in Huntington's disease (HD).
Johns Hopkins researchers have identified a natural mechanism that might one day be used to block the expression of the mutated gene known to cause Huntingtonâ€™s disease.
A team of scientists, led by researchers at the University of California, San Diego School of Medicine, have uncovered a novel mechanism regulating gene expression and transcription linked to Spinocerebellar ataxia 7, an inherited neurological disorder.
McMaster University researchers have discovered a new drug target that may be effective at preventing the onset of Huntington's disease, working much the same way heart medications slow the progression of heart disease and reduce heart attacks.
Researchers successfully characterized the earliest structural formation of the disease type of the protein that causes Huntington's disease.
In Huntington's disease, the mutant protein known as huntingtin leads to the degeneration of a part of the brain known as the basal ganglia, causing the motor disturbances that represent one of the most defining features of the fatal disease.
- A trick or prank.